Kepler Capital Markets set a €122.00 ($137.08) price objective on Merck KGaA (FRA:MRK) in a research note issued to investors on Wednesday, Borsen Zeitung reports. The firm currently has a sell rating on the healthcare company’s stock.
A number of other equities analysts have also recently issued reports on the company. HSBC set a €101.00 ($113.48) price objective on Merck KGaA and gave the stock a neutral rating in a report on Monday, May 18th. Deutsche Bank set a €110.00 ($123.60) target price on Merck KGaA and gave the company a neutral rating in a report on Thursday, May 21st. Nord/LB set a €110.00 ($123.60) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Friday, May 15th. DZ Bank restated a buy rating on shares of Merck KGaA in a report on Tuesday, May 19th. Finally, UBS Group set a €108.00 ($121.35) target price on Merck KGaA and gave the company a neutral rating in a research note on Thursday, May 14th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of €108.50 ($121.91).
Merck KGaA stock opened at €106.85 ($120.06) on Wednesday. Merck KGaA has a fifty-two week low of €76.60 ($86.07) and a fifty-two week high of €115.00 ($129.21). The firm’s fifty day moving average price is €104.06 and its 200-day moving average price is €106.00.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Read More: 12b-1 Fees
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.